Neurocrine Biosciences, Inc.
Financials
Valuation Metrics
Neurocrine Biosciences, Inc.'s Market Cap is $14.62B. At end of 2025 it was $14.11B. Ranked #715 of 3,118 in US market (top 23%), #223 of 1,474 on NASDAQ (top 15%), #34 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.62B | US#715/3,118 Sec#34/265 |
| Revenue | $3.37B | US#1,110/3,118 Sec#31/265 |
| Net Income | $706M | US#681/3,118 Sec#25/265 |
| Total Assets | $5.36B | US#1,400/3,118 Sec#37/265 |
| Net Assets | $3.69B | US#845/3,118 Sec#33/265 |
| Employees | 2,000 | US#1,662/3,118 Sec#40/265 |
| Value | ||
| P/E | 20.73x | US#1,168/3,118 Sec#33/265 |
| P/B | 3.96x | US#2,052/3,118 Sec#128/265 |
| PEG | 0.20x | US#321/3,118 Sec#13/265 |
| P/S | 4.33x | US#2,176/3,118 Sec#72/265 |
| EV/EBITDA | 16.00x | US#1,632/3,118 Sec#41/265 |
| FCF Yield | 5.95% | US#1,192/3,118 Sec#36/265 |
| Profitability | ||
| ROE | 19.10% | US#637/3,118 Sec#34/265 |
| ROA | 13.16% | US#299/3,118 Sec#29/265 |
| Op. Margin | 23.38% | US#734/3,118 Sec#37/265 |
| Revenue Growth | 34.42% | US#352/3,118 Sec#57/265 |
| Earnings Growth | 102.56% | US#290/3,118 Sec#13/265 |
| Financial Health | ||
| Debt Ratio | 45.09% | US#512/3,118 Sec#135/265 |
| Total Debt | $402M | US#1,977/3,118 Sec#71/265 |
| FCF | $870M | US#639/3,118 Sec#28/265 |
| Cash | $332M | US#1,342/3,118 Sec#76/265 |
| Current Ratio | 1.87x | US#1,309/3,118 Sec#225/265 |
| Net Debt/EBITDA | 0.08x | US#620/3,118 Sec#35/265 |
| Performance | ||
| 1Y Return | 1.55% | US#1,628/3,118 Sec#134/265 |
| 1M Return | 1.57% | US#1,462/3,118 Sec#85/265 |
| From 52W High | -21.86% | US#1,552/3,118 Sec#91/265 |
| 1Y MDD | -27.15% | US#1,088/3,118 Sec#51/265 |
| Trading | ||
| Volume | 1,613,022 shares | US#1,639/3,118 Sec#161/265 |
| Trading Value | $235M | US#774/3,118 Sec#40/265 |
| Per Share | ||
| EPS | $7.02 | US#471/3,118 Sec#12/265 |
| BPS | $36.73 | US#704/3,118 Sec#12/265 |
Company Info
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.